Human iPSC‑derived models for neurodegeneration, neuroinflammation & preclinical drug discovery
Huntington’s disease
iPSC lines from five HD patients and one asymptomatic carrier. CENSOi019-B line (HTT: 14/127 CAG, now CAG143) displays instability in culture and is associated with accelerated disease onset. Striatal neurons derived from this iPSC line provide a model for longitudinal studies of repeat expansion and neurodegeneration and recapitulate key HD phenotypes: CAG instability, neurite pathology, and functional deficits.
ALS/MND
Mono- and co-culture models encompassing motor neurons and microglia from multiple ALS genotypes, including C9orf72, SOD1, and TDP‑43, consistently recapitulate key disease phenotypes such as neuronal hyperexcitability, altered firing, morphological changes and impaired microglial phagocytosis.
The PRISM ALS consortia is extending access to iPSC-derived cells from 14 sporadic disease lines to accelerate preclinical discovery.
Alzheimer’s disease
A portfolio of sporadic Alzheimer’s disease iPSC lines with APOE genotypes (E2/E3, E3/E3, E3/E4, E4/E4) differentiated into cortical neurons, astrocytes and microglia for complex cell model development and patient‑stratification studies.
Candidate drug testing across multiple iPSC models and neurotoxicity assays
Drug candidate, viral delivery vectors and novel mechanism drug toxicity and activity screening using multi-electrode array (MEA), flow cytometry, cellular imaging, plate-based assays and ‘omics.
iPSC lines from patients and unaffected donors
Library of fully quality-controlled iPSC lines from unaffected and patient donors, including ALS, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, frontotemporal dementia, Friedreich’s ataxia, spinocerebellar ataxia, Nasu-Hakola disease and more.
iPSC-derived neurons and neuroinflammatory cells for advanced in vitro modeling
Cryopreserved functional cortical excitatory neurons, striatal neurons, cortical inhibitory interneurons, microglia, astrocytes and motor neurons shipped globally. Disease‑relevant phenotypes and mono‑culture, co‑culture and complex model formats.
Ensure confidence in your neural workflow with high-quality axoCellsTM cortical excitatory neurons differentiated from human induced pluripotent stem cells (iPSCs). Derived from consenting donor cord blood and fibroblasts, our cortical excitatory neurons have been specifically developed for use in mono-, co- and tri-culture models of neurodegenerative disease and for drug discovery.
Ensure confidence in your workflow with high-quality axoCellsTM cortical inhibitory interneurons, differentiated from human induced pluripotent stem cells (iPSCs). Derived from two different consenting donors (newborn male and 40-50yr old male), our inhibitory interneurons have been specifically developed for use in mono-, co- and tri-culture models to investigate neurodegenerative diseases and for drug discovery.
Ensure confidence in your neural workflow with high-quality axoCellsTM striatal neurons differentiated from human induced pluripotent stem cells (iPSCs). Derived from consenting donor cord blood and fibroblasts, our striatal neurons have been specifically developed for use in mono-, co- and tri-culture models of neurodegenerative disease and for drug discovery.
Ensure confidence in your workflow with high-quality axoCellsTM motor neurons differentiated from human induced pluripotent stem cells (iPSCs). Derived from consenting donor fibroblasts, our motor neurons have been specifically developed for use in powerful in vitro monoculture and co-culture models, microfluidics platforms and for drug discovery.
Ensure confidence in your workflow with high-quality axoCellsTM sensory neurons differentiated from human induced pluripotent stem cells (iPSCs). Derived from healthy consenting donor cord blood, our sensory neurons have been specifically developed for use in neurological microfluidics systems, nociception models and for assessing analgesic drug targets. Our robust, functionally-relevant sensory neurons express over 50 key ion channels and fuel world-leading microfluidic and “organ-on-chip” models.
Ensure confidence in your neural workflow with high-quality axoCellsTM microglia differentiated from human induced pluripotent stem cells (iPSCs). Derived from consenting donor fibroblasts, we’ve specifically designed our production method to equip you with physiologically relevant cells, by mimicking the in vivo pathway of development for brain-resident macrophages.
Ensure confidence in your workflow with high-quality axoCellsTM astrocytes differentiated from human induced pluripotent stem cells (iPSCs) and assay-ready in just 48 hours. Derived from consenting donor cord blood, our astrocytes have been specifically developed for use in powerful in vitro monoculture models, and complex co-culture systems for drug discovery.
Specialist services
Services include reprogramming from patient cohort material and gene-editing. Custom differentiation of our iPSC lines, or client lines to multiple neuronal and glial cell types. Preclinical drug discovery services, assay development, target validation, mode-of-action and safety.
